Article Abstract

Adjuvant therapy in renal cell carcinoma—is pharmacogenomics assessment another element to select our patients?

Authors: Vincenzo Di Nunno, Veronica Mollica, Lidia Gatto, Matteo Santoni, Giulia Sorgentoni, Nicola Battelli, Francesco Massari


Adjuvant therapy in resected renal cell carcinoma (RCC) is a discussed and complex issue due to conflicting results obtained in several clinical trials exploring different agents in this setting (1-4).